Countries Request a quote
KLOW — Alphagenics vial
Regenerative · Skin and Beauty

KLOW

GHK-Cu + BPC-157 + TB-500 + KPV

Combination of research peptides in tissue regeneration and inflammation

Components4
Total80mg
Available presentations
Certificate of analysis (COA)
80mg
Request a quote Quick guide Research protocol View evidence Reconstitution calculator Physician login

About KLOW

KLOW extends the GLOW combination with KPV, the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH), studied for its anti-inflammatory activity.

The set brings together four lines of research: collagen synthesis (GHK-Cu), angiogenesis and soft-tissue healing (BPC-157), cell migration and re-epithelialization (TB-500) and modulation of NF-κB inflammatory signaling (KPV). Two molecules are sold under the name TB-500, the N-acetylated fragment Ac-LKKTETQ (short chain) and full-length 43-amino-acid thymosin β4 (long chain); the form present in each lot is stated on its certificate of analysis, and the finding cited for TB-500 comes from full-length thymosin β4.

Quick guide · 5 key points

KLOW: tissue repair plus KPV

KLOW adds KPV, an anti-inflammatory fragment of the hormone α-MSH, to the three repair peptides in GLOW. Here are five things the research shows.

View research protocolProtocol (PDF) Open guide (PDF) Download guide
  1. 1

    Four peptides, two goals

    GHK-Cu, BPC-157 and TB-500 (depending on the lot, the short-chain Ac-LKKTETQ fragment or long-chain full-length thymosin β4; the cited study used full-length thymosin β4) have been studied for collagen, blood vessels and wound closure. KPV (Lys-Pro-Val) is the tail end of α-MSH: it keeps the anti-inflammatory effect without the pigmentation effect. The evidence is for each component on its own.1,4,6

    4Peptides: three for repair and one anti-inflammatory
  2. 2

    KPV: less gut inflammation in mice

    In human intestinal cells, nanomolar KPV has been associated with inhibition of NF-κB and fewer inflammatory cytokines. It enters cells through the PepT1 transporter. In two mouse models of colitis, oral KPV has been associated with less colitis.2

    PepT1Transporter that carries KPV into cells
  3. 3

    KPV: a brake on NF-κB in the airways

    In human bronchial cells, KPV has been associated with dose-dependent inhibition of NF-κB, MMP-9 activity and IL-8 and eotaxin release. The proposed mechanism is blocking p65 from entering the nucleus.3

    NF-κBCore inflammatory pathway inhibited by KPV in human cells
  4. 4

    The three repair components

    GHK-Cu has been associated with more collagen in human fibroblasts at nanomolar doses. In rats, BPC-157 has been associated with better recovery of a cut Achilles tendon, and full-length thymosin β4 (the long chain of TB-500, not the fragment) with up to 61% more re-epithelialization of skin wounds by day 7.4,5,6

    +61%Re-epithelialization with full-length thymosin β4 at day 7, in rats
  5. 5

    How strong the evidence is

    KPV data come from cells and animals. In 32 rats, BPC-157 + TB-500 (form not specified) added no benefit over either one alone. Full-length thymosin β4 (not the short-chain fragment) reached phase 2 trials in skin ulcers, and BPC-157 has only three pilot studies in humans. No published study of all four together was found.2,3,9,7,8

    Phase 2Most advanced stage reached by one component (full-length thymosin β4)
References
  1. Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. PMID 18612139
  2. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PMID 18061177
  3. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PMID 22837805
  4. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-6. PMID 3169264
  5. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-83. PMID 14554208
  6. Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-8. PMID 10469335
  7. Treadwell T, et al. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012;1270:37-44. PMID 23050815
  8. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID 40789979
  9. Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926

Components per vial

Reference amounts of the formulation. The physicochemical data correspond to each individual peptide.

GHK-Cu

50 mg
GlyHisLys · Cu²⁺
Molecular formula
C14H22CuN6O4
Molecular weight
401.9 g/mol
CAS number
89030-95-5
PubChem CID
71587328
Length
3 aa + Cu

BPC-157

10 mg
G1E2P3P4P5G6K7P8A9D10D11A12G13L14V15
Molecular formula
C62H98N16O22
Molecular weight
1419.5 g/mol
CAS number
137525-51-0
PubChem CID
9941957
Length
15 aa

TB-500 (Ac-LKKTETQ / Tβ4)

10 mg
Length
Depends on the lot (see certificate of analysis): Ac-LKKTETQ fragment, short chain (7 aa; C38H68N10O14; 889.0 g/mol), or full-length thymosin β4, long chain (43 aa; C212H350N56O78S; 4963.4 g/mol)

KPV

10 mg
LysProVal
Molecular formula
C16H30N4O4
Molecular weight
342.4 g/mol
CAS number
67727-97-3
PubChem CID
125672
Length
3 aa

Five findings from studies

Summary of results reported in the scientific literature. Each finding describes what was observed in the cited study, in its specific population and conditions; it does not constitute a therapeutic indication.

  1. Preclinical

    KPV: in murine models of colitis, KPV has shown a reduction in intestinal inflammation, with cellular uptake through the PepT1 transporter.

    Dalmasso G et al. Gastroenterology. 2008;134:166-178 · PMID 18061177
  2. In vitro

    KPV: in human bronchial epithelial cells, inhibition of NF-κB activation and of the secretion of pro-inflammatory chemokines (IL-8, eotaxin) has been observed.

    Land SC. Int J Physiol Pathophysiol Pharmacol. 2012;4:59-73 · PMID 22837805
  3. In vitro

    GHK-Cu: in human fibroblasts it has shown increased collagen synthesis at nanomolar concentrations.

    Maquart FX et al. FEBS Lett. 1988;238:343-346 · PMID 3169264
  4. Preclinical

    BPC-157: in a rat Achilles tendon transection model it has been associated with better functional and biomechanical recovery.

    Staresinic M et al. J Orthop Res. 2003;21:976-983 · PMID 14554208
  5. Preclinical

    TB-500 long chain (full-length thymosin β4): in a rat skin wound model, full-length thymosin β4 has shown an increase in re-epithelialization of up to 61% at day 7; this result does not come from the short-chain fragment.

    Malinda KM et al. J Invest Dermatol. 1999;113:364-368 · PMID 10469335

More in Regenerative · Skin and Beauty

GHK-CuGLOWSNAP-8Melanotan 2 Spray